Ocular stock rises as eye drug implant OTX-TKI shows promise in vision disorder in trial

Sep. 27, 2022 7:07 AM ETOcular Therapeutix, Inc. (OCUL), PFEREGN, BAYRY, BAYZFBy: Ravikash, SA News Editor

Aged female eye with wrinkled skin


Ocular Therapeutix (NASDAQ:OCUL) said its eye implant OTX-TKI was seen to be safe and well tolerated in patients as per interim 7-month data from a U.S. phase 1 trial to treat wet age-related macular degeneration (wet AMD).


Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.